Zeon Corporation
ZEOOF
Other OTC9.35
USD
- -
- -
ISIN
JP3725400000
CUSIP
98945B107
Return %
Stock
S&P500
1Y
- -
17.85
3Y
-3.11
64.56
5Y
-42.28
69.89
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Tetsuya Toyoshima
- Full Time Employees
- 4,425
- Sector
- Basic Materials
- Industry
- Chemicals - Specialty
- Address
- Shin Marunouchi Center Building Tokyo TY Japan 100-8246
- IPO Date
- Dec 20, 2018
- Website
- zeon.co.jp
- Similar Companies
- Business
- Zeon Corporation is a chemicals manufacturer specializing in synthetic rubbers, specialty materials, and medical products. Founded in 1950 and headquartered in Tokyo, Japan, Zeon produces a broad range of products including synthetic rubber such as solution styrene-butadiene rubber (S-SBR) and emulsion SBR (E-SBR); specialty synthetic elastomers; synthetic latex; high-performance resins; plastic films; specialty chemicals; lithium-ion battery materials like sealants, electrode binders, and functional layer binders; and medical devices focused on cardiovascular and digestive systems. Its products serve diverse markets including automotive components, electronics, medical, and lithium-ion battery industries across Japan and global markets. In recent developments, Zeon has been advancing sustainability and innovation by building a bench-scale facility for highly efficient butadiene production from plant-based ethanol and enhancing its S-SBR production technology with new equipment in Singapore for fuel-efficient tires. The company also signed a strategic investment in the clean technology firm Syzygy Plasmonics to develop combustion-free chemical reactors, reflecting its commitment to decarbonization. In healthcare, Zeon agreed to transfer its medical device businesses in gastrointestinal and cardiovascular fields to Kaneka Corporation in late 2025, reorganizing its medical-related operations. Additionally, Zeon acquired US-based Edge Precision Manufacturing to strengthen its biochemical analytical device molding business, facilitating expansion in healthcare and life sciences in the US and Europe. The company is also advancing production capabilities with Mitsubishi Heavy Industries handling the engineering and construction of a new Cyclo Olefin Polymer plant scheduled for completion in 2028. Zeon operates primarily in Japan with significant global outreach through subsidiaries and strategic partnerships, delivering products that support automotive, healthcare, electronics, and sustainable energy sectors. The company continues to invest in research and development of specialty chemicals and sustainable technologies, reinforcing its market leadership in synthetic rubbers, specialty elastomers, and advanced materials.